Expert Opinion on Emerging Drugs

Papers
(The median citation count of Expert Opinion on Emerging Drugs is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs56
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity49
Bruton’s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis33
Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials27
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer26
Emerging drugs for the treatment of diabetic retinopathy20
Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)19
Emerging synthetic drugs for the treatment of liver cirrhosis15
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer15
Emerging drugs for the treatment of neuromyelitis optica13
New drugs under development for COPD13
Emerging 5-HT receptor antagonists for the treatment of Schizophrenia13
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials13
Emerging therapies in β-thalassemia: toward a new era in management12
Behçet’s disease uveitis: is there a need for new emerging drugs?12
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma12
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update11
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials11
Emerging drugs for the treatment of adult MOG-IgG-associated diseases11
Emerging therapeutics in Huntington’s disease10
Designing phase II clinical trials in Friedreich ataxia10
Treatments in the COVID-19 pandemic: an update on clinical trials10
Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials10
Emerging drugs for the treatment of light chain amyloidosis10
Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists10
Emerging drugs for the treatment of epidermolysis bullosa9
Clinical trials and novel therapeutics in dermatomyositis9
Emerging drugs for treatment of focal segmental glomerulosclerosis9
Emerging topical drugs for the treatment of rosacea9
Emerging therapies for dry eye disease9
Emerging antiviral therapies and drugs for the treatment of influenza8
Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma8
Emerging drugs for the treatment of hidradenitis suppurativa8
Emerging drugs for the treatment of chronic pruritic diseases8
Emerging immune checkpoint inhibitors for the treatment of head and neck cancers7
Emerging muscarinic receptor antagonists for the treatment of asthma7
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia7
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors7
Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials7
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials6
Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials6
Emerging drugs for the treatment of myasthenia gravis6
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials6
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa6
Emerging drugs for the treatment of postsurgical pain6
Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients6
Emerging biological therapies for the treatment of age-related macular degeneration6
Emerging therapeutics for the management of COVID 196
Emerging drugs for the treatment of alopecia areata6
Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer5
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria5
Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials5
Emerging drugs for the treatment of basal cell carcinoma5
Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials5
Emerging drugs for the treatment of chronic myelomonocytic leukemia5
An update on emerging drugs for the treatment of hypercholesterolemia4
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma4
Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors4
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma4
Emerging drugs for the treatment of hepatocellular carcinoma4
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials3
Emerging drugs for the treatment of Waldenström macroglobulinemia3
Emerging medicines to improve the basic defect in cystic fibrosis3
Emerging drugs for the treatment of inflammatory bowel disease3
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials3
Emerging drugs for the prevention of migraine3
Emerging drugs for the treatment of cutaneous T-cell lymphoma3
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia3
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials3
A review of emerging factor XI inhibitors3
Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia3
Emerging drugs for the treatment of glaucoma: a review of phase II & III trials3
Emerging biological therapies for the treatment of malignant pleural mesothelioma3
0.011113166809082